Antibody Contract Manufacturing Market Outlook Report 2024-2033 | Size, Trends, Analysis, Insights, Overview

"The new report published by The Business Research Company, titled Antibody Contract Manufacturing Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the antibody contract manufacturing market size has grown rapidly in recent years. It will grow from $12.84 billion in 2023 to $14.71 billion in 2024 at a compound annual growth rate (CAGR) of 14.6%. The antibody contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $25.27 billion in 2028 at a compound annual growth rate (CAGR) of 14.5%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12665&type=smp

Surge In Clinical Trials Fuels The Antibody Contract Manufacturing Market Growth
The rising number of clinical trials is expected to propel the growth of the antibody contract manufacturing market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. The number of clinical trials involving antibody-based therapeutics or diagnostics expands, for high-quality antibodies, ensuring a timely and compliant supply for clinical trials. For instance, in May 2023, according to ClinicalTrials.gov, a part of the National Institutes of Health (NIH), a US-based government agency responsible for conducting and supporting medical research, in all 50 states of the United States and 221 countries, the number of registered clinical trials studies climbed from 399,499 in 2022 to 437,533 in 2023. Additionally, around 241,498 studies, or 53% of the total, were registered outside the United States, compared to 140,492 studies (31%) registered just in the United States. Therefore, the rising number of clinical trials is driving the growth of the antibody contract manufacturing market.

Technological Innovations Redefines The Antibody Contract Manufacturing Market
Technological advancements are a key trend gaining popularity in the antibody contract manufacturing market. Major companies operating in the antibody contract manufacturing market are adopting new technologies to sustain their position in the market. For instance, in October 2021, Merck KGaA, a Germany-based science and technology company, introduced ChetoSensar, an innovative technology aimed at addressing solubility challenges in antibody-drug conjugates (ADCs). Merck KGaA intends to leverage their expertise in contract development manufacturing for the development of next-generation antibody-drug conjugates and improve the effectiveness of high-potency active pharmaceutical ingredients (HPAPIs) by enhancing the solubility of these compounds through the innovative ChetoSensar technology.

The antibody contract manufacturing market covered in this report is segmented -

1) By Product: Monoclonal Antibodies, Polyclonal Antibodies, Other Products
2) By Source: Mammalian, Microbial
3) Scale Of Operation: Preclinical, Clinical, Commercial
4) By End-User: Biopharmaceutical Companies, Research Laboratories, Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12665&type=discount

Major companies operating in the antibody contract manufacturing market report are AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Fujifilm Holdings Corporation, Eurofins Scientific SE, Lonza Group AG, Labcorp Drug Development, Catalent Inc., Charles River Laboratories International Inc., Merck KGaA, Samsung Biologics Co. Ltd., Wuxi Biologics Cayman Inc, Pierre Fabre Group, Siegfried Holding AG, Recipharm AB, Emergent BioSolutions Inc., Aenova Group, Cambrex Corporation, Aldevron LLC, Novasep Holding SAS, Synthon, KBI Biopharma Inc., Nitto Avecia Pharma Services Inc., Cytovance Biologics Inc., AGC Biologics S.p.A.

Contents of the report:
1. Executive Summary
2. Antibody Contract Manufacturing Market Report Structure
3. Antibody Contract Manufacturing Market Trends And Strategies
4. Antibody Contract Manufacturing Market - Macro Economic Scenario
5. Antibody Contract Manufacturing Market Size And Growth
…..
27. Antibody Contract Manufacturing Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/antibody-contract-manufacturing-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.